PAULA WAKI LOPES DA ROSA
Projetos de Pesquisa
Unidades Organizacionais
LIM/18 - Laboratório de Carboidratos e Radioimunoensaios, Hospital das Clínicas, Faculdade de Medicina
5 resultados
Resultados de Busca
Agora exibindo 1 - 5 de 5
- Differential expression of genes encoding proteins of the HGF/MET system in insulinomas(2015) MURAT, Cahue de Bernardis; ROSA, Paula Waki Lopes da; FORTES, Maria Angela Henriques Zanella; CORREA, Luciana; MACHADO, Marcel Cerqueira Cesar; NOVAK, Estela Maria; SIQUEIRA, Sheila Aparecida Coelho; PEREIRA, Maria Adelaide Albergaria; CORREA-GIANNELLA, Maria Lucia; GIANNELLA-NETO, Daniel; GIORGI, Ricardo RodriguesBackground: Insulinomas are the most common functional pancreatic neuroendocrine tumors, whereas histopathological features do not predict their biological behaviour. In an attempt to better understand the molecular processes involved in the tumorigenesis of islet beta cells, the present study evaluated the expression of genes belonging to the hepatocyte growth factor and its receptor (HGF/MET) system, namely, MET, HGF; HGFAC and ST14 (encode HGF activator and matriptase, respectively, two serine proteases that catalyze conversion of pro-HGF to active HGF); and SPINT1 and SPINT2 (encode serine peptidase inhibitors Kunitz type 1 and type 2, respectively, two inhibitors of HGF activator and of matriptase). Methods: Quantitative real-time reverse transcriptase polymerase chain reaction was employed to assess RNA expression of the target genes in 24 sporadic insulinomas: 15 grade 1 (G1), six grade 2 (G2) and three hepatic metastases. Somatic mutations of MET gene were searched by direct sequencing of exons 2, 10, 14, 16, 17 and 19. Results: Overexpression of MET was observed in the three hepatic metastases concomitantly with upregulation of the genes encoding HGF and matriptase and downregulation of SPINT1. A positive correlation was observed between MET RNA expression and Ki-67 proliferation index while a negative correlation was detected between SPINT1 expression and the mitotic index. No somatic mutations were found in MET gene. Conclusion: The final effect of the increased expression of HGF, its activator (matriptase) and its specific receptor (MET) together with a decreased expression of one potent inhibitor of matriptase (SPINT1) is probably a contribution to tumoral progression and metastatization in insulinomas.
- Differences in the gut microbiota of women according to ultra- processed food consumption(2023) FERNANDES, Ariana E.; ROSA, Paula W. L.; MELO, Maria E.; MARTINS, Roberta C. R.; SANTIN, Fernanda G. O.; MOURA, Aline M. S. H.; COELHO, Graziele S. M. A.; SABINO, Ester C.; CERCATO, Cintia; MANCINI, Marcio C.Background and aims: High consumption of ultra-processed food (UPF) has been associated with increased risk of obesity and other metabolic diseases, and this dietary pattern seems to be responsible for chronic changes in the gut microbiota. The aim of this study was to assess the associations of UPF with the gut microbiota and obesity-associated biometrics in women. Methods and results: This cross-sectional study examined 59 women. The following parameters were evaluated: food consumption using NOVA classification, anthropometric and metabolic parameters, and gut microbiome by next-generation sequencing. The mean age was 28.0 & PLUSMN; 6.6 years. The mean caloric intake was 1624 & PLUSMN; 531 kcal, of which unprocessed or minimally processed food (G1) accounted for 52.4 & PLUSMN; 13.5%, and UPF accounted for 31.4 & PLUSMN; 13.6%. Leptin levels adjusted for fat mass were negatively associated with G1 and positively associated with UPF. We found 15 species in the gut microbiota that correlated with G1 (3 positively and 12 negatively) and 9 species associated with UPF (5 positively and 4 negatively). Conclusion: Higher consumption of UPF was directly associated with leptin resistance, and this study suggests that the consumption of UPF or G1 may affect the composition of the gut micro biota. & COPY; 2022 The Italian Diabetes Society, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition and the Department of Clinical Medicine and Surgery, Federico II University.
- Triple A Syndrome: Preliminary Response to the Antioxidant N-Acetylcysteine Treatment in a Child(2017) FRAGOSO, Maria Candida Barisson Villares; ALBUQUERQUE, Edoarda Vasco de Albuquerque; CARDOSO, Ana Luiza de Almeida; ROSA, Paula Waki Lopes da; PAULO, Rodrigo Bomeny de; SCHIMIZU, Maria Heloisa Massola; SEGURO, Antonio Carlos; PASSARELLI, Marisa; KOEHLER, Katrin; HUEBNER, Angela; ALMEIDA, Madson Q.; LATRONICO, Ana Claudia; ARNHOLD, Ivo Jorge Prado; MENDONCA, Berenice BilharinhoIntroduction: Triple A syndrome (AAAS) is a rare autosomal recessive disorder characterized by alacrima, achalasia, ACTH-resistant adrenal insufficiency, autonomic dysfunction, and progressive neurodegeneration. Increased oxidative stress, demonstrated in patients' fibroblasts in vitro, may be a central disease mechanism. N-acetylcysteine protects renal function in patients with kidney injuries associated with increased oxidative stress and improves viability of AAAS-knockdown adrenal cells in vitro. Patient and Results: A boy diagnosed with AAAS presented with short stature and increased oxidative stress in vivo assessed by increased thiobarbituric acid reactive substances (TBARS), which are markers of lipid peroxidation, and by the susceptibility of LDL to oxidation and the capacity of HDL to prevent it. A homozygous missense germline mutation (c.523G>T, p.Val175Phe) in AAAS was identified. N-acetylcysteine (600 mg orally, twice daily) decreased oxidative stress but did not change the patient's growth pattern. Conclusions: An increase in oxidative stress is reported for the first time in vivo in an AAAS patient. N-acetylcysteine was capable of decreasing TBARS levels, reducing the susceptibility of LDL to oxidation and improving the antioxidant role of HDL. The long-term effect of antioxidant treatment should be evaluated to determine the real benefit for the prevention of the degenerative process in AAAS. (C) 2017 S. Karger AG, Basel
- Fecal microbiota transplantation in patients with metabolic syndrome and obesity: A randomized controlled trial(2023) PONTE NETO, Alberto Machado da; CLEMENTE, Aniele Cristine Ott; ROSA, Paula Waki; RIBEIRO, Igor Braga; FUNARI, Mateus Pereira; NUNES, Gabriel Cairo; MOREIRA, Luana; SPARVOLI, Luiz Gustavo; CORTEZ, Ramon; TADDEI, Carla Romano; MANCINI, Marcio C.; MOURA, Eduardo Guimaraes Hourneaux deBACKGROUNDMetabolic syndrome is a multifactorial disease, and the gut microbiota may play a role in its pathogenesis. Obesity, especially abdominal obesity, is associated with insulin resistance, often increasing the risk of type two diabetes mellitus, vascular endothelial dysfunction, an abnormal lipid profile, hypertension, and vascular inflammation, all of which promote the development of atherosclerotic cardiovascular disease.AIMTo evaluate the outcomes of fecal microbiota transplantation (FMT) in patients with metabolic syndrome.METHODSThis was a randomized, single-blind placebo-controlled trial comparing FMT and a sham procedure in patients with metabolic syndrome. We selected 32 female patients, who were divided into eight groups of four patients each. All of the patients were submitted to upper gastrointestinal endoscopy. In each group, two patients were randomly allocated to undergo FMT, and the other two patients received saline infusion. The patients were followed for one year after the procedures, during which time anthropometric, bioimpedance, and biochemical data were collected. The patients also had periodic consultations with a nutritionist and an endocrinologist. The primary end point was a change in the gut microbiota.RESULTSThere was evidence of a postprocedural change in microbiota composition in the patients who underwent FMT in relation to that observed in those who underwent the sham procedure. However, we found no difference between the two groups in terms of the clinical parameters evaluated.CONCLUSIONThere were no significant differences in biochemical or anthropometric parameters, between the two groups evaluated. Nevertheless, there were significant postprocedural differences in the microbiota composition between the placebo group. To date, clinical outcomes related to FMT remain uncertain.
bookPart Procedimentos estéticos(2016) FLORESI, Ana Clara Franco; RêGO, Maria Antônia Simões; SENçO, Sofia Barbieri de; ROSA, Paula Waki Lopes da; CORDáS, Táki Athanássios